PNC Financial Services Group Inc. Purchases 3,990 Shares of Illumina, Inc. $ILMN

PNC Financial Services Group Inc. increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 23.5% during the 1st quarter, Holdings Channel reports. The firm owned 20,986 shares of the life sciences company’s stock after purchasing an additional 3,990 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Illumina were worth $2,587,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in ILMN. Elyxium Wealth LLC bought a new position in shares of Illumina in the fourth quarter valued at approximately $25,000. Creative Capital Management Investments LLC lifted its holdings in Illumina by 160.0% during the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after acquiring an additional 120 shares during the period. TD Waterhouse Canada Inc. bought a new stake in Illumina during the fourth quarter worth $26,000. Laurel Wealth Advisors LLC purchased a new position in Illumina in the fourth quarter worth $26,000. Finally, Quarry LP bought a new position in Illumina in the 3rd quarter valued at $32,000. 89.42% of the stock is owned by institutional investors.

Insider Transactions at Illumina

In other news, SVP Christensen Jakob Wedel sold 700 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total value of $97,328.00. Following the sale, the senior vice president owned 15,056 shares of the company’s stock, valued at $2,093,386.24. The trade was a 4.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $180.00, for a total transaction of $110,700.00. Following the sale, the insider owned 20,953 shares in the company, valued at $3,771,540. The trade was a 2.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,003,769 shares of company stock valued at $155,710,908. 2.90% of the stock is currently owned by insiders.

Illumina Stock Up 1.9%

ILMN stock opened at $192.98 on Wednesday. The stock has a fifty day moving average of $173.22 and a 200-day moving average of $146.03. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $199.14. The company has a market capitalization of $29.20 billion, a price-to-earnings ratio of 35.09, a PEG ratio of 2.80 and a beta of 1.47. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. The business had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 5.22 earnings per share for the current year.

Analysts Set New Price Targets

ILMN has been the subject of several research analyst reports. Piper Sandler raised their target price on Illumina from $170.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 1st. Sanford C. Bernstein started coverage on shares of Illumina in a report on Friday, June 26th. They issued a “market perform” rating and a $185.00 price target on the stock. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target for the company in a research report on Thursday, May 14th. Citigroup raised their price objective on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a report on Monday, May 4th. Finally, Wall Street Zen lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Saturday, July 18th. Nine equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $156.88.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.